期刊文献+

以卟啉类衍生物为光敏剂的光动力疗法的靶点研究进展 被引量:3

Studies on the Target of Photodynamic Therapy with Porphyrin Derivatives as Photosensitizer
原文传递
导出
摘要 目的介绍以卟啉类衍生物为光敏剂的光动力学疗法(PDT)的靶点研究进展。方法从光敏剂的分布特性、活性氧的产生与作用、PDT中细胞凋亡的线粒体途径方面阐明线粒体为卟啉类衍生物光动力反应的主要靶点。结论卟啉类衍生物作为最常用的光敏剂,能选择性浓集于靶部位产生活性氧,从而导致靶细胞的破坏。目前越来越多报道表明,在PDT中线粒体可能是最主要的靶点。 OBJECTIVE Introduce the studies progress on the target of photodynamic therapy (PDT) with porphyrin derivatives as photosensitizers. METHODS This article discussed the evidences of mitochondria as the target site in PDT with three lines of data: the distribution characters of porphyrin derivatives as the photosensitizers in the cell; reactive oxygen species, the mitochondrial pathway for cell apoptosis in PDT. RESULTS Porphyrin derivatives as the most common photosensitizers could selectively concentrated at the target cell to produce reactive oxygen species, which lead to the destruction of target cells. CONCLUSION About where is the PDT target site in the cell, there is no concensus in the early studies, but increasing studies found that mitochondria may be the main target in PDT.
出处 《中国现代应用药学》 CAS CSCD 2013年第4期445-449,共5页 Chinese Journal of Modern Applied Pharmacy
基金 贵州省科学技术基金项目(黔科合[2007]2226)
关键词 线粒体 卟啉 光动力疗法 细胞凋亡 mitochondria porphyrin photodynamic therapy cell apoptosis
  • 相关文献

参考文献33

  • 1LU Y, JIAO R, CHEN X,et al. Methylene blue-mediatedphotodynamic therapy induces mitochondria-dependentapoptosis in HeLa cell [J]. J Cell Biochem, 2008, 105(6):1451-1460.
  • 2HILF R. Mitochondria are targets of photodynamic therapy [J].J Bioenerg Biomembr, 2007,39(1): 85-89.
  • 3邵红霞,刘蓉,吴琦,高瑞霄.光敏剂在光动力疗法中的作用[J].医学综述,2008,14(22):3404-3407. 被引量:9
  • 4ALI-SEYED M, BHUVANESWARI R, SOO K C, et al.Photolon?-photosensitization induces apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes [J].Int J Oncol, 2011,39(4): 821-831.
  • 5MICHAEL BORSCH. Targeting cytochrome C oxidase inmitochondria with Pt( II )-porphyrins for PhotodynamicTherapy[C]//DAVID H. KESSEL. Optical Methods for TumorTreatment and Detection: Mechanisms and Techniques inPhotodynamic Therapy XIX. San Francisco, SPIE, 2010:75510G-75510G-11.
  • 6KEIR S T, DEWHIRST M W, KIRKPATRICK J P, et al.Cellular redox modulator, ortho Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in thetreatment of brain tumors [J]. Anticancer Agents Med Chem,2011, 11(2):202-212.
  • 7MEI W J, WEI X Y, LI W N,et al. Cytotoxic andDNA-binding properties of two ruthnium porphyrincomplexes [J]. Transition Met Chem, 2008,33(8): 1033-1058.
  • 8MROZ P,YAROSLAVSKY A,KHARKWAL G B, et al. Celldeath pathways in photodynamic therapy of cancer [J].Cancers, 2011,3(2): 2516-2539.
  • 9MROZ P,BHAUMIK J, DOGUTAN D K,et al. Imidazolemetalloporphyrins as photosensitizers for photodynamictherapy: role of molecular charge, central metal and hydroxylradical production [J]. Cancer Lett, 2009,282(1): 63-76.
  • 10QUIOGUE G, SAGGU S, HUNG H I, et al. Signaling fromlysosomes enhances mitochondria-mediated photodynamictherapy in cancer cells [J]. Proc Soc Photo Opt Instrum Eng,2009,7380(73800C): 1-8.

二级参考文献56

共引文献14

同被引文献23

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部